Work

Supplementary Table 1 from Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Table 1. Characteristics of all patients studied.

DOI: 10.1158/1078-0432.22460525.v1

Authors: Martin Skarzynski, Carsten U. Niemann, Yuh Shan Lee, Sabrina Martyr, Irina Maric, Dalia Salem, Maryalice Stetler-Stevenson, Gerald E. Marti, Katherine R. Calvo, Constance Yuan, Janet Valdez, Susan Soto, Mohammed Z.H. Farooqui, Sarah E.M. Herman, Adrian Wiestner

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361919685

Cites:

Cited by:

Related to: 10